Journal issues > Issue 8, December 2019 > Highlights in squamous cell carcinoma of the head and neck

Highlights in squamous cell carcinoma of the head and neck

During the 2019 annual meeting of the European Society for Medical Oncology (ESMO) the most recent advances in recurrent/metastatic (R/M) and locoregionally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC) as well as nasopharyngeal carcinoma were discussed. In R/M HNSCC the safety and efficacy of monalizumab alone and in combination with cetuximab was assessed and the ELAN trials tried to assess the management of elderly HNSCC patients. In LA HNSCC the efficacy of Debio 1143 in combination with chemoradiotherapy as well as the dominance of cisplatin over cetuximab in association with radiotherapy were studied. In nasopharyngeal carcinoma, results were presented on the benefit of radiotherapy to chemotherapy with cisplatin and fluorouracil. Finally, Bossi et al. demonstrated that in non-endemic countries, patients with nasopharyngeal carcinoma have the same survival figures and prognostic factors as patients in endemic areas.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top